Q1 Earnings Forecast for FULC Issued By Leerink Partnrs

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.35) for the quarter, down from their prior estimate of ($0.30). The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics' Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.32) EPS and FY2026 earnings at ($1.19) EPS.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03).

Several other research firms have also commented on FULC. Royal Bank of Canada reissued a "sector perform" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. HC Wainwright restated a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $8.63.

Remove Ads

Fulcrum Therapeutics Trading Up 0.9 %

Shares of FULC traded up $0.03 during trading hours on Friday, hitting $3.27. The company had a trading volume of 401,900 shares, compared to its average volume of 467,435. The company has a market capitalization of $176.51 million, a PE ratio of -10.55 and a beta of 2.03. Fulcrum Therapeutics has a one year low of $2.86 and a one year high of $13.70. The company's fifty day moving average price is $4.08 and its two-hundred day moving average price is $4.46.

Institutional Trading of Fulcrum Therapeutics

Several large investors have recently added to or reduced their stakes in FULC. BNP Paribas Financial Markets acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth about $38,000. China Universal Asset Management Co. Ltd. lifted its stake in Fulcrum Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock valued at $43,000 after acquiring an additional 4,701 shares during the period. Walleye Capital LLC acquired a new stake in Fulcrum Therapeutics during the 3rd quarter valued at approximately $59,000. Intech Investment Management LLC purchased a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at $62,000. Finally, Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics in the fourth quarter worth $78,000. Hedge funds and other institutional investors own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.